Breaks Categories: News

WednesdayMay 08, 2024 3:31 pm

NetworkNewsBreaks – Phone.com Launches Breakthrough Conversational-Voice Artificial Intelligence Service

Phone.com has unveiled its newest offering: AI-Connect. The new service is a conversational-voice artificial intelligence (“AI”) service that brings together natural language processing (“NLP”), natural language understanding (“NLU”) and large language models (“LLM”) to enable exceptional intent recognition and the ability to create a goal-oriented, fluid dialogue. The new service elevates call handling and appointment-setting for a wide array of sectors, including service-oriented businesses, independent contractors, retail, restaurants and hospitality, real estate and solopreneurs. AI-Connect can handle inbound leads, manage schedules and appointments, and even answer questions in natural conversations with callers. “AI-Connect is much more than just a service or…

Continue Reading

WednesdayMay 08, 2024 3:00 pm

NetworkNewsBreaks – DeFi Technologies Inc.’s (CBOE CA: DEFI) (GR: R9B) (OTCQB: DEFTF) Subsidiary Valour Inc. Positioned to Capitalize on Opportunities in Digital Assets Space

DeFi Technologies (CBOE CA: DEFI) (GR: R9B) (OTCQB: DEFTF), a financial technology company that pioneers the convergence of traditional capital markets with the world of decentralized finance (“DeFi”), has announced that its subsidiary Valour Inc., a leading issuer of exchange traded products (“ETPs”) that provide simplified access to digital assets, has successfully repaid US$19.5 million in outstanding loans. According to the announcement, as of April 30, 2024, Valour has fully repaid balances of US$6 million and US$13.5 million, which were secured by BTC and ETH collateral, respectively. No further equity or debt was raised to repay the loans. The announcement…

Continue Reading

WednesdayMay 08, 2024 2:39 pm

NetworkNewsBreaks – D-Wave Quantum Inc. (NYSE: QBTS) Announces Participation in Upcoming Needham Technology, Media and Consumer Conference

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, will be participating in this month’s 19th Annual Needham Technology, Media and Consumer Conference. The three-day conference is scheduled for May 14–16, 2024. D-Wave CEO Dr. Alan Baratz is slated to participate in a fireside chat that begins at 1:30 p.m. ET on May 16. During the discussion, Dr. Baratz will provide an overview of the company’s latest advancements and its strategic direction, as well as the measurable outcomes that quantum computing is delivering for businesses today. An archived version of the webcast will be made available on…

Continue Reading

WednesdayMay 08, 2024 2:13 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Dosing of Human Pilot Study No. 2, GLP-1-H24-2

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its second human pilot study, GLP-1-H24-2, is underway and the first dosing visit for all nine study participants has concluded. The three-arm, crossover study will compare three 7 mg semaglutide dose formulations: A positive control Rybelsus(R) swallowed tablet (already dosed); DehydraTECH-semaglutide swallowed capsules; and, for the first time ever, an in-mouth dissolvable DehydraTECH-semaglutide oral tablet. According to the announcement, the second DehydraTECH study arm will use a Rybelsus(R) composition processed with DehydraTECH that is compliant with the U.S. Food and Drug Administration’s Inactive Ingredient Database…

Continue Reading

WednesdayMay 08, 2024 2:04 pm

NetworkNewsBreaks – SuperCom Ltd. (NASDAQ: SPCB) Schedules Release of Q1 2024 Financial Results, Conference Call

SuperCom (NASDAQ: SPCB), a global provider of secured solutions for the e-government, IoT and cybersecurity sectors, will hold a conference call at 10 a.m. Eastern Time on Wednesday, May 15, 2024, to discuss its financial results for the first quarter ended March 31, 2024. According to the announcement, financial results will be issued in a press release prior to the call. Interested parties should visit https://nnw.fm/f1qcL to register for the event and dial 888-506-0062 (U.S. toll-free), 1-809-423-853 (Israel toll-free) or 973-528-0011 (international) and state SuperCom as the access code to join the call. Attendees are asked to join via the…

Continue Reading

WednesdayMay 08, 2024 1:56 pm

NetworkNewsBreaks – Advanced Gold Exploration Inc. (CSE: AUEX) (OTC: AUHIF) (FSE: 4TG) Notes Industry Interest in Copper, Provides Update on Its Buck Lake Project

Advanced Gold Exploration (CSE: AUEX) (OTC: AUHIF) (FSE: 4TG), a junior mining company bringing an entirely different approach to the mining industry, released a statement noting the interest in copper and the recent increases in the price of the metal. The company is interested in copper and its role in electric vehicle development as well as reducing greenhouse-gas emissions and is developing its own copper project, Buck Lake. The statement noted that copper is instrumental in the commodities super cycle and that the world needs more copper, making exploration key in the supply. The company observed that its Buck Lake…

Continue Reading

WednesdayMay 08, 2024 1:24 pm

NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) Releases Q1 2024 Financial Numbers, Operation Highlights

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., are reporting on first-quarter 2024 financial results and operating highlights for its CNM-Au8 clinical program for amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). Clene Nanomedicine is a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases. Highlights of the report include the news that data from the long-term extension of Clene’s phase 2 VISIONARY-MS clinical trial of CNM-Au8® exhibits significant evidence of repair and remyelination across multiple paraclinical endpoints; the publication of an article in the “ACS Pharmacology & Translational Science,” a journal that publishes…

Continue Reading

WednesdayMay 08, 2024 8:30 am

NetworkNewsBreaks – NanoViricides Inc. (NYSE American: NNVC) Lead Drug Candidate Indicates Strong Orthopoxvirus Activity

NanoViricides (NYSE American: NNVC), a global leader in broad-spectrum antiviral nanomedicines, is reporting that, in a lethal animal model, its lead drug candidate, NV-387, showed ultra-broad antiviral activity, including activity against the orthopoxvirus family, including smallpox and mpox. According to the announcement, in the model of lung infection by Ectromelia virus, oral dosing with NV-387 showed an increase in lifespan of mice comparable to oral treatment with tecovirimat (TPOXX[R], SIGA), which is currently the approved drug against smallpox. “We have completed a lethality animal study wherein animals were infected with ectromelia virus into the lungs directly,” stated the company in…

Continue Reading

TuesdayMay 07, 2024 3:16 pm

NetworkNewsBreaks – Sekur Private Data Ltd. (CSE: SKUR) (OTCQX: SWISF) (FSE: GDT0) Inks Agreement Marking Entry into Telecom, Fintech Markets

Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FSE: GDT0), a premier Swiss-hosted secure and private communications platform, has signed a letter of intent marking the company’s deliberate expansion into the telecom and fintech markets. According to the announcement, Sekur signed an agreement for a planned contribution of a mobile virtual network operator (“MVNO”) telecommunications company; the agreement also outlined details of a $500,000 cash infusion into Sekur Private Data by Cuentas Inc. (OTC: CUEN). Headquartered in Miami, Florida, Cuentas seamlessly integrates fintech, mobile telecommunications and real estate to serve the Hispanic demographic, particularly unbanked and underbanked communities. The contribution Cuentas…

Continue Reading

TuesdayMay 07, 2024 2:37 pm

NetworkNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Marks Important Step in Advancing Lucid-21-302

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces the submission to ethics of a trial. Entitled “A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants,” the clinical trial application is submitted for review by a human ethics review committee (“HREC”) in Australia. The step is necessary to obtain permission to initiate the multiple ascending dose (“MAD”) trial, which follows the Phase-1 single ascending dose (“SAD”)…

Continue Reading